# Taspoglutide: A Deep Dive into P Taspoglutide - an overview | ScienceDirect Topics eptide Engineering and Structural Design
In the realm of advanced peptide chemistry, few molecules have garnered as much technical interest as taspoglutide. As a hobbyist and enthusiast in the analytical study of peptide chains, I have spent significant time examining its structural architecture and the historical data surrounding its development. This review captures the Taspoglutide - Drug Targets, Indications, Patents - Synapse essence of this compound from a purely ob Taspoglutide - Wikipedia jective, technical perspective, focusing on i Taspoglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that was developed for the treatment of type 2 diabetes. ts molecular design rather than clinical utilization.
To answer the core question of what is taspoglutide, it is essential to view it as a triumph of structural biology. At its foundation, it is a synthetic, long-acting analog of human glucagon-like peptide-1 (GLP-1). While the native hormone is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), taspoglutide was specifically engineered to resist this enzymatic degradation, thereby extending its functional half-life.
The molecule is defined by a specific 30-amino acid sequence. Its enhanced stability is primarily attributed to substitutions at positions 2 and 29, specifically utilizing alpha-aminoisobutyric acid (Aib). These modifications allow the peptide to maintain a robust alpha-helical secondary structure, which is critical for its affinity to target receptors.
The Engineering Behind the Taspoglutide Structure
From a structural standpoint, the taspoglutide structure is a masterclass in peptide stability. The amino acid sequence modification, which involves substituting the alanine at position 8 and the glycine at position 35 of the native hGLP-1(7-36) precursor, creates a more rigid peptide backbone.
High-resolution techniques, including cryo-electron microscopy (cryo-EM), have been utilized in recent years to map the dynamics of this compound. Observations show that the C-terminus, specifically beyond the Arg34 position, significantly extends this helical stability. For those interested in the chemical nomenclature, its molecular formula is C152H232N40O45, and it is cataloged with the chemical identity CID 56842233.
Historical Context: The Collaboration with Roche
The development saga involving taspoglutide and Roche—often in partnership with Ipsen—serves as a case study for the rigorous development process peptides undergo. During the late 2000s, this compound was the subject of significant investigation, with phase III clinical programs designed to compare its efficacy profiles against existing standards like sitagliptin, insulin glargine, and pioglitazone.
During these historical trials, researchers noted the emergence of anti-taspoglutide antibodies in a segment of the participant groups, a factor that influenced subsequent developments in the field of synthetic analogs. Despite its discontinuation as a pharmaceutical agent, the technical data generated regarding its pharmacokinetics remains a cornerstone for current researchers working with GLP-1 Taspoglutide - Wikipedia receptor agonists.
Personal Synthesis and Observations
In my own review of structural datasets, I am consistently impressed by how the inclusion of Aib residues acts as a "shield" against metabolic enzymes. When comparing taspoglutide to other GLP-1 analogs, the precision with which the polypeptide sequence was altered highlights how minor changes in the primary structure can have profound impacts on structural integrity and biochemical interaction sites.
Whether one is examining its 3D variability or its binding affinity, taspoglutide remains an essential entry in the historical ledger of peptide research. Its legacy lives on in the structural design principles applied to newer, more stable peptide constructs currently being explored in laboratories worldwide.
***
*Discla Anti-taspoglutide antibodies were confirmed in 46% of patients. Taspoglutide demonstrated better efficacy on glycemic control and … imer: This content is for informa Taspoglutide is a human GLP-1 analogue with 2 alpha-aminoisobutyric acid substitutions replacing Ala (8) and Gly (35) of h GLP-1 (7 … tional and educational purposes based on publicly available historical and chemical data. It does not constitute medical advice or recommendations for human use.*
# Taspoglutide: A Deep Dive into P Taspoglutide - an overview | ScienceDirect Topics eptide Engineering and Structural Design
In the realm of advanced peptide chemistry, few molecules have garnered as much technical interest as taspoglutide. As a hobbyist and enthusiast in the analytical study of peptide chains, I have spent significant time examining its structural architecture and the historical data surrounding its development. This review captures the Taspoglutide - Drug Targets, Indications, Patents - Synapse essence of this compound from a purely ob Taspoglutide - Wikipedia jective, technical perspective, focusing on i Taspoglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that was developed for the treatment of type 2 diabetes. ts molecular design rather than clinical utilization.
To answer the core question of what is taspoglutide, it is essential to view it as a triumph of structural biology. At its foundation, it is a synthetic, long-acting analog of human glucagon-like peptide-1 (GLP-1). While the native hormone is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), taspoglutide was specifically engineered to resist this enzymatic degradation, thereby extending its functional half-life.
The molecule is defined by a specific 30-amino acid sequence. Its enhanced stability is primarily attributed to substitutions at positions 2 and 29, specifically utilizing alpha-aminoisobutyric acid (Aib). These modifications allow the peptide to maintain a robust alpha-helical secondary structure, which is critical for its affinity to target receptors.
The Engineering Behind the Taspoglutide Structure
From a structural standpoint, the taspoglutide structure is a masterclass in peptide stability. The amino acid sequence modification, which involves substituting the alanine at position 8 and the glycine at position 35 of the native hGLP-1(7-36) precursor, creates a more rigid peptide backbone.
High-resolution techniques, including cryo-electron microscopy (cryo-EM), have been utilized in recent years to map the dynamics of this compound. Observations show that the C-terminus, specifically beyond the Arg34 position, significantly extends this helical stability. For those interested in the chemical nomenclature, its molecular formula is C152H232N40O45, and it is cataloged with the chemical identity CID 56842233.
Historical Context: The Collaboration with Roche
The development saga involving taspoglutide and Roche—often in partnership with Ipsen—serves as a case study for the rigorous development process peptides undergo. During the late 2000s, this compound was the subject of significant investigation, with phase III clinical programs designed to compare its efficacy profiles against existing standards like sitagliptin, insulin glargine, and pioglitazone.
During these historical trials, researchers noted the emergence of anti-taspoglutide antibodies in a segment of the participant groups, a factor that influenced subsequent developments in the field of synthetic analogs. Despite its discontinuation as a pharmaceutical agent, the technical data generated regarding its pharmacokinetics remains a cornerstone for current researchers working with GLP-1 Taspoglutide - Wikipedia receptor agonists.
Personal Synthesis and Observations
In my own review of structural datasets, I am consistently impressed by how the inclusion of Aib residues acts as a "shield" against metabolic enzymes. When comparing taspoglutide to other GLP-1 analogs, the precision with which the polypeptide sequence was altered highlights how minor changes in the primary structure can have profound impacts on structural integrity and biochemical interaction sites.
Whether one is examining its 3D variability or its binding affinity, taspoglutide remains an essential entry in the historical ledger of peptide research. Its legacy lives on in the structural design principles applied to newer, more stable peptide constructs currently being explored in laboratories worldwide.
***
*Discla Anti-taspoglutide antibodies were confirmed in 46% of patients. Taspoglutide demonstrated better efficacy on glycemic control and … imer: This content is for informa Taspoglutide is a human GLP-1 analogue with 2 alpha-aminoisobutyric acid substitutions replacing Ala (8) and Gly (35) of h GLP-1 (7 … tional and educational purposes based on publicly available historical and chemical data. It does not constitute medical advice or recommendations for human use.*